SCM
TGTX icon

Soleus Capital Management’s TG Therapeutics TGTX Stock Holding History

Soleus Capital Management’s Portfolio TGTX Stock Details TGTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$161M Sell
2,927,895
-1,101,424
-27% -$45.1M 5.54% 3
2026
Q1 		$134M Buy
4,029,319
+890,007
+28% +$26.5M 5.42% 3
2025
Q4 		$93.6M Sell
3,139,312
-705,419
-18% -$23M 3.45% 6
2025
Q3 		$139M Buy
3,844,731
+1,600,796
+71% +$52.7M 6.99% 2
2025
Q2 		$80.8M Sell
2,243,935
-602,768
-21% -$22.4M 5.35% 3
2025
Q1 		$112M Buy
2,846,703
+165,461
+6% +$5.57M 8.08% 2
2024
Q4 		$80.7M Buy
2,681,242
+146,702
+6% +$4.21M 5.07% 3
2024
Q3 		$59.3M Sell
2,534,540
-1,111,022
-30% -$24.3M 4.59% 3
2024
Q2 		$64.9M Buy
3,645,562
+477,106
+15% +$7.61M 5.72% 1
2024
Q1 		$48.2M Buy
3,168,456
+2,518,456
+387% +$40.1M 3.58% 6
2023
Q4 		$11.1M Sell
650,000
-2,234,382
-77% -$26M 1.23% 27
2023
Q3 		$24.1M Buy
2,884,382
+2,448,882
+562% +$34.1M 2.22% 12
2023
Q2 		$10.8M Sell
435,500
-314,800
-42% -$8.13M 1.2% 24
2023
Q1 		$11.3M Buy
750,300
+512,300
+215% +$7.78M 1.17% 26
2022
Q4 		$2.82M Buy
+238,000
New +$1.73M 0.4% 49

Other funds holding TGTX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
ClearBridge Investments
ClearBridge Investments New York $121B AUM 27.52% 1-Year Est. Return
CAM
Congress Asset Management Boston, Massachusetts $16.3B AUM 42.69% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Soleus Capital Management's TGTX Position: Q2 2026 in Review

Soleus Capital Management reduced its TG Therapeutics (TGTX) stake by 27% in Q2 2026, selling an estimated $45.1M and leaving 2,927,895 shares worth $161M. The position accounts for 5.54% of the portfolio, ranked #3.

Soleus Capital Management first reported a position in TGTX in Q4 2022 and has held it in 15 quarters since. 427 funds tracked by Wall St. Rank hold TGTX as of Q2 2026.

  • Soleus Capital Management held 2,927,895 shares of TG Therapeutics worth $161M as of Q2 2026.
  • Soleus Capital Management sold 1,101,424 TG Therapeutics shares in Q2 2026, an estimated $45.1M.
  • TG Therapeutics made up 5.54% of Soleus Capital Management's portfolio in Q2 2026, its #3 holding.
  • Soleus Capital Management first reported a position in TG Therapeutics in Q4 2022 and has held it in 15 quarters since.
  • 427 funds tracked by Wall St. Rank held TG Therapeutics as of Q2 2026.

Based on Soleus Capital Management's 13F filing for Q2 2026, filed 11 Aug 2026.